Drug Trial Radar · NCT06329141
A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
99
Actual
Start
Jul 22, 2024
Primary completion
Dec 16, 2025
Study completion Jan 7, 2026
Sponsor
- Lead sponsor
- GlaceumIndustry
- Sponsor type
- Industry
- Collaborators
- Kyunghee University Medical Center; Korea University Guro Hospital; Samsung Medical Center; Severance Hospital; Inje University; Hallym University Medical Center; The Catholic University of Korea; Uijeongbu St. Mary Hospital
- First posted
- Mar 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
1. Study Objective \- To assess the efficacy and safety of vutiglabridin in early Parkindson's disease patients 2. Background Glaceum Inc. has evaluated the safety, tolerability, and pharmacokinetic/pharmacodynamic properties of vutiglabridin in healthy subjects through its Phase 1 trials, and is planning to perform this Phase 2a trial to assess the efficacy and safety of vutiglabridin in early Parkinson's disease patients. 3. Study Design and Protocol This study is a randomized, double-blind, placebo-controlled, parallel-group trial. Subjects deemed eligible to participate in this study based on the inclusion/exclusion criteria will be assigned a subject number and randomized to one of the 3 treatment groups - 1 group receiving a placebo - in a 1:1:1 ratio. Subjects will be randomized to double-blind treatments and will receive a once-daily oral dose of the investigational product for 24 weeks according to the study protocol. Several parameters (i.e., MDS-UPDRS, CGI-C, K-NMSS, modified Hoehn-Yahr stage and SNBR) will be evaluated to assess the efficacy of vutiglabridin. Assessments including measurement of vital signs, 12-lead ECG, clinical laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed to evaluate the safety and tolerability of vutiglabridin. Blood samples will be collected for pharmacokinetic assessment.
Conditions
- Parkinson Disease
Interventions
VutiglabridinDrug
Once-daily oral administration
PlaceboDrug
Once-daily oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in MDS-UPDRS Part III SubscoreTime frame: From baseline to Week 24
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Inje University Busan Paik Hospital
Busan, South Korea
Inje University Sanggye Paik Hospital
Seoul, South Korea
KyungHee University Medical Center
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
The Catholic University of Korea
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Hallym University Medical Center
Anyang-si, Gyeonggi-do, South Korea
The Catholic University of Korea Uijeongbu St.Marys Hostpial
Uijeongbu-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.